4//SEC Filing
Chang David D 4
Accession 0001214659-22-004085
CIK 0001737287other
Filed
Mar 16, 8:00 PM ET
Accepted
Mar 17, 5:59 PM ET
Size
8.3 KB
Accession
0001214659-22-004085
Insider Transaction Report
Form 4
Chang David D
DirectorPresident and CEO
Transactions
- Sale
Common Stock
2022-03-15$7.65/sh−23,648$180,879→ 2,289,652 total
Holdings
- 856,044(indirect: See footnote)
Common Stock
- 856,044(indirect: See footnote)
Common Stock
- 1,201,108(indirect: See footnote)
Common Stock
Footnotes (6)
- [F1]Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.59 to $7.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F3]Includes 1021 shares of the Issuer's common stock acquired by the reporting person on March 15, 2022 pursuant to an employee stock purchase program.
- [F4]Securities held in the name of the Chang 2006 Family Trust.
- [F5]Securities held in the name of the JEC 2019 Trust dated October 1, 2019.
- [F6]Securities held in the name of the RTC 2019 Trust dated October 1, 2019.
Documents
Issuer
Allogene Therapeutics, Inc.
CIK 0001737287
Entity typeother
Related Parties
1- filerCIK 0001611024
Filing Metadata
- Form type
- 4
- Filed
- Mar 16, 8:00 PM ET
- Accepted
- Mar 17, 5:59 PM ET
- Size
- 8.3 KB